Skip to main content
Erschienen in: Inflammation 2/2012

01.04.2012

Association Between C-Reactive Protein and Type 2 Diabetes in a Tunisian Population

verfasst von: Hanen Belfki, Samir Ben Ali, Souha Bougatef, Decy Ben Ahmed, Najet Haddad, Awatef Jmal, Monia Abdennebi, Habiba Ben Romdhane

Erschienen in: Inflammation | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to investigate the association of CRP levels with type 2 diabetes (T2D) and its related variables in a sample of the Tunisian population. Our sample included 129 patients with T2D and 187 control subjects. Body mass index (BMI), plasma lipids, glucose, insulin, and CRP concentrations were measured for each participant. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. T2D was defined as a fasting plasma glucose (FPG) level ≥ 7.0 mmol/L, the use of anti-diabetic drugs, or both. Statistical analyses were performed using SPSS 11.5. A significant difference in mean values of BMI, plasma lipids, FPG, insulin, and HOMA-IR was observed between subjects with and without T2D. CRP level was significantly higher in subjects with T2D than those without (p = 0.023), and this result persisted even after adjustment for age, gender, BMI, smoking, and alcohol consumption. In both diabetes statuses, log CRP was significantly associated with FPG, insulin, and HOMA-IR. Subjects with elevated CRP levels (>5 mg/L) had an increased risk of T2D (OR = 2.02, 95% CI 1.18–3.46, p = 0.010) than those whose CRP levels were less or equal to 5 mg/L. Even after adjustment for potentially confounding factors, the risk of T2D was still increased in subjects with elevated CRP levels (OR = 1.91, 95% CI 1.08–3.36, p = 0.025). These results suggest that elevated CRP levels are independently associated with T2D.
Literatur
1.
Zurück zum Zitat Lyra, R., M. Oliveira, D. Lins, and N. Cavalcanti. 2006. Prevention of type 2 diabetes mellitus. Arq Bras Endocrinol Metab 50: 239–249.CrossRef Lyra, R., M. Oliveira, D. Lins, and N. Cavalcanti. 2006. Prevention of type 2 diabetes mellitus. Arq Bras Endocrinol Metab 50: 239–249.CrossRef
2.
Zurück zum Zitat Bogaert, Y.E., and R.W. Schrier. 2011. Into the future: prevention of diabetes. Contributions to Nephrology 170: 256–263.PubMedCrossRef Bogaert, Y.E., and R.W. Schrier. 2011. Into the future: prevention of diabetes. Contributions to Nephrology 170: 256–263.PubMedCrossRef
3.
Zurück zum Zitat Wong, T.Y., N. Cheung, W.T. Tay, J.J. Wang, T. Aung, S.M. Saw, S.C. Lim, E.S. Tai, and P. Mitchell. 2008. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology 115: 1869–1875.PubMedCrossRef Wong, T.Y., N. Cheung, W.T. Tay, J.J. Wang, T. Aung, S.M. Saw, S.C. Lim, E.S. Tai, and P. Mitchell. 2008. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology 115: 1869–1875.PubMedCrossRef
4.
Zurück zum Zitat Howard, B.V., B.L. Rodriguez, P.H. Bennett, M.I. Harris, R. Hammam, L.H. Kuller, T.A. Pearson, and J. Wylie-Rosett. 2002. Prevention Conference VI: Diabetes and cardiovascular disease: writing group I: epidemiology. Circulation 105: 132–137.CrossRef Howard, B.V., B.L. Rodriguez, P.H. Bennett, M.I. Harris, R. Hammam, L.H. Kuller, T.A. Pearson, and J. Wylie-Rosett. 2002. Prevention Conference VI: Diabetes and cardiovascular disease: writing group I: epidemiology. Circulation 105: 132–137.CrossRef
5.
Zurück zum Zitat Nabipour, I., K. Vahdat, S.M. Jafari Seyed, S. Beigi, M. Assadi, F. Azizi, and Z. Sanjdideh. 2008. Elevated high sensitivity c-reactive protein is associated with type 2 diabetes mellitus: the Persian Gulf healthy heart study. Endocrine Journal 55: 717–722.PubMedCrossRef Nabipour, I., K. Vahdat, S.M. Jafari Seyed, S. Beigi, M. Assadi, F. Azizi, and Z. Sanjdideh. 2008. Elevated high sensitivity c-reactive protein is associated with type 2 diabetes mellitus: the Persian Gulf healthy heart study. Endocrine Journal 55: 717–722.PubMedCrossRef
6.
Zurück zum Zitat Pickup, J.C., M.B. Mattock, G.D. Chusney, and D. Burt. 1997. NIDDM as disease of the immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40: 1286–1292.PubMedCrossRef Pickup, J.C., M.B. Mattock, G.D. Chusney, and D. Burt. 1997. NIDDM as disease of the immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40: 1286–1292.PubMedCrossRef
7.
Zurück zum Zitat Pickup, J.C., and M.A. Crook. 1998. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41: 1241–1248.PubMedCrossRef Pickup, J.C., and M.A. Crook. 1998. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41: 1241–1248.PubMedCrossRef
8.
Zurück zum Zitat Morohoshi, M., K. Fujisawa, I. Uchimura, and F. Numano. 1996. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes 45: 954–959.PubMedCrossRef Morohoshi, M., K. Fujisawa, I. Uchimura, and F. Numano. 1996. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes 45: 954–959.PubMedCrossRef
9.
Zurück zum Zitat Guha, M., W. Bai, J.L. Nadler, and R. Natarajan. 2000. Molecular mechanisms of tumor necrosis factor α gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. Journal of Biological Chemistry 275: 17728–17739.PubMedCrossRef Guha, M., W. Bai, J.L. Nadler, and R. Natarajan. 2000. Molecular mechanisms of tumor necrosis factor α gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. Journal of Biological Chemistry 275: 17728–17739.PubMedCrossRef
10.
Zurück zum Zitat Hirschfield, G., and M. Pepys. 2003. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM 96: 793.PubMedCrossRef Hirschfield, G., and M. Pepys. 2003. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM 96: 793.PubMedCrossRef
11.
Zurück zum Zitat Pearson, T.A., G.A. Mensah, R.W. Alexander, J.L. Anderson, R.O. Cannon 3rd, M. Criqui, Y.Y. Fadl, S.P. Fortmann, Y. Hong, G.L. Myers, N. Rifai, S.C. Smith Jr., K. Taubert, R.P. Tracy, and F. Vinicor. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499–511.PubMedCrossRef Pearson, T.A., G.A. Mensah, R.W. Alexander, J.L. Anderson, R.O. Cannon 3rd, M. Criqui, Y.Y. Fadl, S.P. Fortmann, Y. Hong, G.L. Myers, N. Rifai, S.C. Smith Jr., K. Taubert, R.P. Tracy, and F. Vinicor. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499–511.PubMedCrossRef
12.
Zurück zum Zitat Ridker, P.M., M. Cushman, M.J. Stampfer, R.P. Tracy, and C.H. Hennekens. 1997. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. The New England Journal of Medicine 336: 973–979.PubMedCrossRef Ridker, P.M., M. Cushman, M.J. Stampfer, R.P. Tracy, and C.H. Hennekens. 1997. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. The New England Journal of Medicine 336: 973–979.PubMedCrossRef
13.
Zurück zum Zitat Yeh, E.T., and J.T. Willerson. 2003. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 107: 370–371.PubMedCrossRef Yeh, E.T., and J.T. Willerson. 2003. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 107: 370–371.PubMedCrossRef
14.
Zurück zum Zitat Ridker, P.M. 2003. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107: 363–369.PubMedCrossRef Ridker, P.M. 2003. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107: 363–369.PubMedCrossRef
15.
Zurück zum Zitat Liuzzo, G., L.M. Biasucci, J.R. Gallimore, R.L. Grillo, A.G. Rebuzzi, M.B. Pepys, and A. Maseri. 1994. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. New Engl J Med 331: 417–424.PubMedCrossRef Liuzzo, G., L.M. Biasucci, J.R. Gallimore, R.L. Grillo, A.G. Rebuzzi, M.B. Pepys, and A. Maseri. 1994. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. New Engl J Med 331: 417–424.PubMedCrossRef
16.
Zurück zum Zitat Ridker, P.M., C.H. Hennekens, J.E. Buring, and N. Rifai. 2000. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New Engl J Med 342: 836–843.PubMedCrossRef Ridker, P.M., C.H. Hennekens, J.E. Buring, and N. Rifai. 2000. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New Engl J Med 342: 836–843.PubMedCrossRef
17.
Zurück zum Zitat Festa, A., R. D'Agostino Jr., G. Howard, L. Mykkänen, R.P. Tracy, and S.M. Haffner. 2000. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42–47.PubMed Festa, A., R. D'Agostino Jr., G. Howard, L. Mykkänen, R.P. Tracy, and S.M. Haffner. 2000. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42–47.PubMed
18.
Zurück zum Zitat Pradhan, A.D., J.E. Manson, N. Rifai, J.E. Buring, and P.M. Ridker. 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327–334.PubMedCrossRef Pradhan, A.D., J.E. Manson, N. Rifai, J.E. Buring, and P.M. Ridker. 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327–334.PubMedCrossRef
19.
Zurück zum Zitat Nakanishi, S., K. Yamane, N. Kamei, M. Okubo, and N. Kohno. 2003. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care 26: 2754–2757.PubMedCrossRef Nakanishi, S., K. Yamane, N. Kamei, M. Okubo, and N. Kohno. 2003. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care 26: 2754–2757.PubMedCrossRef
20.
Zurück zum Zitat Thorand, B., J. Baumert, H. Kolb, C. Meisinger, L. Chambless, W. Koenig, and C. Herder. 2007. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Diabetes Care 30: 854–860.PubMedCrossRef Thorand, B., J. Baumert, H. Kolb, C. Meisinger, L. Chambless, W. Koenig, and C. Herder. 2007. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Diabetes Care 30: 854–860.PubMedCrossRef
21.
Zurück zum Zitat Hu, G., P. Jousilahti, J. Tuomilehto, R. Antikainen, J. Sundvall, and V. Salomaa. 2009. Association of serum C-reactive protein level with sex-specific type 2 diabetes risk: a prospective Finnish study. Journal of Clinical Endocrinology and Metabolism 94: 2099–2105.PubMedCrossRef Hu, G., P. Jousilahti, J. Tuomilehto, R. Antikainen, J. Sundvall, and V. Salomaa. 2009. Association of serum C-reactive protein level with sex-specific type 2 diabetes risk: a prospective Finnish study. Journal of Clinical Endocrinology and Metabolism 94: 2099–2105.PubMedCrossRef
22.
Zurück zum Zitat Krakoff, J., T. Funahashi, C.D. Stehouwer, C.G. Schalkwijk, S. Tanaka, Y. Matsuzawa, S. Kobes, P.A. Tataranni, R.L. Hanson, W.C. Knowler, and R.S. Lindsay. 2003. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26: 1745–1751.PubMedCrossRef Krakoff, J., T. Funahashi, C.D. Stehouwer, C.G. Schalkwijk, S. Tanaka, Y. Matsuzawa, S. Kobes, P.A. Tataranni, R.L. Hanson, W.C. Knowler, and R.S. Lindsay. 2003. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26: 1745–1751.PubMedCrossRef
23.
Zurück zum Zitat Dehghan, A., I. Kardys, M.P. de Maat, A.G. Uitterlinden, E.J. Sijbrands, A.H. Bootsma, T. Stijnen, A. Hofman, M.T. Schram, and J.C. Witteman. 2007. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 56: 872–878.PubMedCrossRef Dehghan, A., I. Kardys, M.P. de Maat, A.G. Uitterlinden, E.J. Sijbrands, A.H. Bootsma, T. Stijnen, A. Hofman, M.T. Schram, and J.C. Witteman. 2007. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 56: 872–878.PubMedCrossRef
24.
Zurück zum Zitat Lee, C.C., A.I. Adler, M.S. Sandhu, S.J. Sharp, N.G. Forouhi, S. Erqou, R. Luben, S. Bingham, K.T. Khaw, and N.J. Wareham. 2009. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 52: 1040–1047.PubMedCrossRef Lee, C.C., A.I. Adler, M.S. Sandhu, S.J. Sharp, N.G. Forouhi, S. Erqou, R. Luben, S. Bingham, K.T. Khaw, and N.J. Wareham. 2009. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 52: 1040–1047.PubMedCrossRef
25.
Zurück zum Zitat Friedewald, W.T., R.T. Levy, and D.S. Fredrickson. 1972. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the ultracentrifuge. Clinical Chemistry 18: 449–502. Friedewald, W.T., R.T. Levy, and D.S. Fredrickson. 1972. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the ultracentrifuge. Clinical Chemistry 18: 449–502.
26.
Zurück zum Zitat Matthews, D.R., J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.PubMedCrossRef Matthews, D.R., J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.PubMedCrossRef
27.
Zurück zum Zitat Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 1997. Diabetes Care 20:1183–1197. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 1997. Diabetes Care 20:1183–1197.
28.
Zurück zum Zitat Dandona, P., A. Aljada, A. Chaudhuri, and A. Bandyopadhyay. 2003. The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complication in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 88: 2422–2429.PubMedCrossRef Dandona, P., A. Aljada, A. Chaudhuri, and A. Bandyopadhyay. 2003. The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complication in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 88: 2422–2429.PubMedCrossRef
29.
Zurück zum Zitat Doi, Y., Y. Kiyohara, M. Kubo, T. Ninomiya, Y. Wakugawa, K. Yonemoto, M. Iwase, and M. Iida. 2005. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 28: 2497–2500.PubMedCrossRef Doi, Y., Y. Kiyohara, M. Kubo, T. Ninomiya, Y. Wakugawa, K. Yonemoto, M. Iwase, and M. Iida. 2005. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 28: 2497–2500.PubMedCrossRef
30.
Zurück zum Zitat Freeman, D.J., J. Norrie, M.J. Caslake, A. Gaw, I. Ford, G.D. Lowe, D.S. O'Reilly, C.J. Packard, N. Sattar, and West of Scotland Coronary Prevention Study. 2002. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51: 1596–1600.PubMedCrossRef Freeman, D.J., J. Norrie, M.J. Caslake, A. Gaw, I. Ford, G.D. Lowe, D.S. O'Reilly, C.J. Packard, N. Sattar, and West of Scotland Coronary Prevention Study. 2002. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51: 1596–1600.PubMedCrossRef
31.
Zurück zum Zitat Huffman, F.G., S. Whisner, G.G. Zarini, and S. Nath. 2010. Waist circumference and BMI in relation to serum high sensitivity C-reactive protein (hs-CRP) in Cuban Americans with and without type 2 diabetes. International Journal of Environmental Research and Public Health 7: 842–852.PubMedCrossRef Huffman, F.G., S. Whisner, G.G. Zarini, and S. Nath. 2010. Waist circumference and BMI in relation to serum high sensitivity C-reactive protein (hs-CRP) in Cuban Americans with and without type 2 diabetes. International Journal of Environmental Research and Public Health 7: 842–852.PubMedCrossRef
32.
Zurück zum Zitat Shemesh, T., K.G. Rowley, A. Jenkins, J. Brimblecombe, J.D. Best, and K. O'Dea. 2007. Differential association of C-reactive protein with adiposity in men and women in an Aboriginal community in northeast Arnhem Land of Australia. International Journal of Obesity 31: 103–108.PubMedCrossRef Shemesh, T., K.G. Rowley, A. Jenkins, J. Brimblecombe, J.D. Best, and K. O'Dea. 2007. Differential association of C-reactive protein with adiposity in men and women in an Aboriginal community in northeast Arnhem Land of Australia. International Journal of Obesity 31: 103–108.PubMedCrossRef
33.
Zurück zum Zitat Baumann, H., and J. Gauldie. 1990. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Molecular Biology & Medicine 7: 147–159. Baumann, H., and J. Gauldie. 1990. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Molecular Biology & Medicine 7: 147–159.
34.
Zurück zum Zitat Hotamisligil, G.S., P. Arner, J.F. Caro, R.L. Atkinson, and B.M. Spiegelman. 1995. Increased adipose tissue expression of tumor necrosis factor alpha in human obesity and insulin resistance. The Journal of Clinical Investigation 95: 2409–2415.PubMedCrossRef Hotamisligil, G.S., P. Arner, J.F. Caro, R.L. Atkinson, and B.M. Spiegelman. 1995. Increased adipose tissue expression of tumor necrosis factor alpha in human obesity and insulin resistance. The Journal of Clinical Investigation 95: 2409–2415.PubMedCrossRef
35.
Zurück zum Zitat Warren, R.S., H.F. Starnes Jr., J.L. Gabrilove, H.F. Oettgen, and M.F. Brennan. 1987. The acute metabolic effects of tumor necrosis factor administration in humans. Archives of Surgery 122: 1396–1400.PubMedCrossRef Warren, R.S., H.F. Starnes Jr., J.L. Gabrilove, H.F. Oettgen, and M.F. Brennan. 1987. The acute metabolic effects of tumor necrosis factor administration in humans. Archives of Surgery 122: 1396–1400.PubMedCrossRef
36.
Zurück zum Zitat Vgontzas, A.N., D.A. Papanicolaou, E.O. Bixler, A. Kales, K. Tyson, and G.P. Chrousos. 1997. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. Journal of Clinical Endocrinology and Metabolism 82: 1313–1316.PubMedCrossRef Vgontzas, A.N., D.A. Papanicolaou, E.O. Bixler, A. Kales, K. Tyson, and G.P. Chrousos. 1997. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. Journal of Clinical Endocrinology and Metabolism 82: 1313–1316.PubMedCrossRef
37.
Zurück zum Zitat Yamada, S., T. Gotoh, Y. Nakashima, K. Kayaba, S. Ishikawa, N. Nago, Y. Nakamura, Y. Itoh, and E. Kajii. 2001. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population. Jichi Med School Cohort Study. Am J Epidemiol 153: 1183–1190. Yamada, S., T. Gotoh, Y. Nakashima, K. Kayaba, S. Ishikawa, N. Nago, Y. Nakamura, Y. Itoh, and E. Kajii. 2001. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population. Jichi Med School Cohort Study. Am J Epidemiol 153: 1183–1190.
38.
Zurück zum Zitat Saijo, Y., N. Kiyota, Y. Kawasaki, Y. Miyazaki, J. Kashimura, M. Fukuda, and R. Kishi. 2004. Relationship between C-reactive protein and visceral adipose tissue in healthy Japanese subjects. Diabetes, Obesity & Metabolism 6: 249–258.CrossRef Saijo, Y., N. Kiyota, Y. Kawasaki, Y. Miyazaki, J. Kashimura, M. Fukuda, and R. Kishi. 2004. Relationship between C-reactive protein and visceral adipose tissue in healthy Japanese subjects. Diabetes, Obesity & Metabolism 6: 249–258.CrossRef
39.
Zurück zum Zitat Pickup, J.C. 2004. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27: 813–823.PubMedCrossRef Pickup, J.C. 2004. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27: 813–823.PubMedCrossRef
40.
Zurück zum Zitat Grunfeld, C., and K.R. Feingold. 1996. Regulation of lipid metabolism by cytokines during host defense. Nutrition 12: S24–S26.PubMed Grunfeld, C., and K.R. Feingold. 1996. Regulation of lipid metabolism by cytokines during host defense. Nutrition 12: S24–S26.PubMed
41.
Zurück zum Zitat Nishikawa, T., D. Edelstein, X.L. Du, S. Yamaguchi, T. Matsumura, Y. Kaneda, M.A. Yorek, D. Beebe, P.J. Oates, H.P. Hammes, I. Giardino, and M. Brownlee. 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 404: 787–790.PubMedCrossRef Nishikawa, T., D. Edelstein, X.L. Du, S. Yamaguchi, T. Matsumura, Y. Kaneda, M.A. Yorek, D. Beebe, P.J. Oates, H.P. Hammes, I. Giardino, and M. Brownlee. 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 404: 787–790.PubMedCrossRef
42.
Zurück zum Zitat Ceriello, A., and E. Motz. 2004. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arteriosclerosis, Thrombosis, and Vascular Biology 24: 816–823.PubMedCrossRef Ceriello, A., and E. Motz. 2004. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arteriosclerosis, Thrombosis, and Vascular Biology 24: 816–823.PubMedCrossRef
43.
Zurück zum Zitat Cleland, S.J., N. Sattar, J.R. Petrie, N.G. Forouhi, H.L. Elliott, and J.M. Connell. 2000. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Science 98: 531–535.CrossRef Cleland, S.J., N. Sattar, J.R. Petrie, N.G. Forouhi, H.L. Elliott, and J.M. Connell. 2000. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Science 98: 531–535.CrossRef
44.
Zurück zum Zitat Tooke, J. 1999. The association between insulin resistance and endotheliopathy. Diabetes, Obesity & Metabolism 1: S17–S22.CrossRef Tooke, J. 1999. The association between insulin resistance and endotheliopathy. Diabetes, Obesity & Metabolism 1: S17–S22.CrossRef
45.
Zurück zum Zitat Stewart, M.W., D.T. Cirkel, K. Furuseth, J. Donaldson, N. Biswas, M.G. Starkie, C. Phenekos, and A. Hamann. 2006. Effect of metformin plus rosiglitazone compared with metformin alone on glycaemic control in well-controlled type 2 diabetes. Diabetic Medicine 23: 1069–1078.PubMedCrossRef Stewart, M.W., D.T. Cirkel, K. Furuseth, J. Donaldson, N. Biswas, M.G. Starkie, C. Phenekos, and A. Hamann. 2006. Effect of metformin plus rosiglitazone compared with metformin alone on glycaemic control in well-controlled type 2 diabetes. Diabetic Medicine 23: 1069–1078.PubMedCrossRef
46.
Zurück zum Zitat Ridker, P.M., C.P. Cannon, D. Morrow, N. Rifai, L.M. Rose, C.H. McCabe, M.A. Pfeffer, and E. Raunwald. 2005. C-reactive protein levels and outcomes after statin therapy. N Eng J Med 352: 20–28.CrossRef Ridker, P.M., C.P. Cannon, D. Morrow, N. Rifai, L.M. Rose, C.H. McCabe, M.A. Pfeffer, and E. Raunwald. 2005. C-reactive protein levels and outcomes after statin therapy. N Eng J Med 352: 20–28.CrossRef
Metadaten
Titel
Association Between C-Reactive Protein and Type 2 Diabetes in a Tunisian Population
verfasst von
Hanen Belfki
Samir Ben Ali
Souha Bougatef
Decy Ben Ahmed
Najet Haddad
Awatef Jmal
Monia Abdennebi
Habiba Ben Romdhane
Publikationsdatum
01.04.2012
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 2/2012
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-011-9361-1

Weitere Artikel der Ausgabe 2/2012

Inflammation 2/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.